BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Lupus (SLE / lupus nephritis) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for systemic lupus erythematosus: 208 (116 sponsors; 28 newly posted in the last 180 days, 10 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 12.3, rank 55 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 11, Phase 1 77, Phase 2 62, Phase 3 35, Phase 4 4, N/A 19.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN24NA 12, P3 6, P1 3, P2 2, P4 143
Novartis Pharmaceuticals NVS9P1 2, P3 5, P2 212
Biogen BIIB5P3 500
Viatris Innovation GmbH VTRS4P3 402
Bristol-Myers Squibb BMY6P3 3, P1 1, P4 1, NA 120
EMD Serono Research & Development Institute, Inc.3P3 310
Hoffmann-La Roche5P1 1, P3 2, P2 200
UCB Biopharma SRL3P3 2, P1 110
AbbVie ABBV3P3 1, P1 211
Qilu Pharmaceutical Co., Ltd.3P1 2, P3 111
Beeline Medicines Corporation BLNE2P2 1, P3 110
Beijing Mabworks Biotech Co., Ltd.2P3 1, P2 100
Janssen Research & Development, LLC1P3 100
China Immunotech (Beijing) Biotechnology Co., Ltd.6P1 5, NA 102
GlaxoSmithKline5P1 2, P2 1, NA 1, P4 100
Chongqing Precision Biotech Co., Ltd4P1 400
CytoCares Inc3P1 1, EARLY_P1 200
Fate Therapeutics FATE3P2 2, P1 110
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company3P1 2, P2 100
Miltenyi Biomedicine GmbH3P2 2, P1 100
Autolus Limited AUTL2P2 1, P1 100
Beijing Immunochina Medical Science & Technology Co., Ltd.2EARLY_P1 1, P1 100
Cartesian Therapeutics RNAC2P2 201
Chengdu Ucello Biotechnology Co., Ltd.2EARLY_P1 200
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2P2 201

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06859931 Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosusnot yet recruiting120
2026-12 est.P2Ventus Therapeutics U.S., Inc.NCT07260877 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Cutaneous Lupus Erythematosus (CLE); Systemic Lupus Erythematosus; SLE; SLE (Systemic Lupus); CLEactive not recruiting24
2026-12-01 est.P2Cartesian Therapeutics RNACNCT06038474 Descartes-08 for Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE)active not recruiting6
2026-12-31 est.P3Viatris Innovation GmbH VTRSNCT05672576 A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusLupus Erythematosus, Systemicactive not recruiting451
2027-01 est.P2Shanghai Henlius BiotechNCT07038382 A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in PMembranous Nephropathy; Lupus Nephritis (LN)recruiting24
2027-02-01 est.P1/P2Gracell Biotechnologies (Shanghai) Co., Ltd.NCT06530849 A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusRefractory Systemic Lupus Erythematosusactive not recruiting20

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-02P3AstraZeneca AZNNCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusCutaneous Lupus Erythematosusactive not recruiting339
2026-10-20 est.P2/P3Biogen BIIBNCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusSubacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosusactive not recruiting450
2026-10-19 est.P3Bristol-Myers Squibb BMYNCT05620407 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting513
2026-10-19 est.P3Bristol-Myers Squibb BMYNCT05617677 A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosusactive not recruiting516
2026-10 est.P2Immunovant Sciences GmbH IMVTNCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosusactive not recruiting56
2026-10 est.P2Keymed Biosciences Co.LtdNCT06791772 Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)Systemic Lupus Erythematosusnot yet recruiting150
2026-09-30 est.P3Biogen BIIBNCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErytheLupus Erythematosus, Systemicactive not recruiting548
2026-09-27 est.P3Biogen BIIBNCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErytheLupus Erythematosus, Systemicactive not recruiting562
2026-09-24P1/P2Novartis Pharmaceuticals NVSNCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusSystemic Lupus Erythematosus; Lupus Nephritiscompleted21
2026-09-23P2Zenas BioPharma (USA), LLC ZBIONCT06559163 A Study of Obexelimab in Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting190
2026-09-04P2Sanofi SNYNCT05039840 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting109
2026-06-12P2Beeline Medicines Corporation BLNENCT04895696 A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosusactive not recruiting248
2026-06-08P1/P2Nanjing Immunophage Biotech Co., LtdNCT06717815 Phase IIa Study for IPG11406 in Patients With Lupus NephritisLupus Nephritiscompleted24
2026-05-31 est.P1/P2Miltenyi Biomedicine GmbHNCT06347718 CAR-T Cells in Systemic B Cell Mediated Autoimmune DiseaseSystemic Lupus Erythematosus; Systemic Sclerosis; Dermatomyositis; Polymyositisrecruiting24
2026-05-29P1/P2Kyverna Therapeutics KYTXNCT05938725 KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisLupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III; Lupus Nephritis - WHO terminated6

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "systemic lupus erythematosus"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.